MedPath

taVNS for Letter Learning in Dyslexia

Not Applicable
Not yet recruiting
Conditions
Dyslexia
Interventions
Device: sham taVNS
Device: active taVNS
Registration Number
NCT06127550
Lead Sponsor
University of Florida
Brief Summary

This is a pilot study to establish feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) for improving letter-learning in adolescents with dyslexia. The main goals of the study are to 1) evaluate whether children in this age range will tolerate low level stimulation over the course of multiple sessions, 2) determine whether low level taVNS improves novel letter learning in dyslexia, and 3) evaluate the effect of low level taVNS on the brain's response to letters. Participants will complete fMRI before training, immediately after training, and a few weeks after training ends. Training will consist of six 30-minute lessons during which participants will learn novel letter-sound relationships while receiving either active or sham taVNS. Researchers will compare stimulation conditions to determine effect of this device on learning and neural plasticity.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Normal non-verbal IQ
  • Reading scores above 90 on four single word reading measures (typical reader) OR reading scores below 90 on two or more single word reading measures (dyslexia) with or without ADHD
Exclusion Criteria
  • Neurological diagnoses (e.g., autism, epilepsy, etc.)
  • Medications other than those prescribed for ADHD
  • Nonverbal IQ below 80

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham taVNSsham taVNSParticipants will undergo current thresholding but device will be turned off without their knowledge during the training.
Active taVNSactive taVNSParticipants will receive custom current at 5 Hz to the left auricular branch of the vagus nerve while learning new letter-sound relationships.
Primary Outcome Measures
NameTimeMethod
Adverse events4 weeks

Frequency and severity of adverse events will be monitored and evaluated for severity and impact on attrition.

Compliance4 weeks

Percentage of the population that remains engaged in the study and completes all stimulation sessions.

Secondary Outcome Measures
NameTimeMethod
Letter ID6 weeks

Percent correct of learned letter-sound relationships

Decoding6 weeks

Percent correct of pseudowords read in 45 seconds

Automaticity6 weeks

This measure is based on a standardized measure for rapid letter naming in English (CTOPP-Rapid Automatized Naming) in which the participant is shown a grid of many letters in Hebrew and are asked to read the grid as quickly and accurately as possible while being timed.

Trial Locations

Locations (1)

University of Florida

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath